INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 179 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q2 2016. The put-call ratio across all filers is 0.65 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2020 | $428,000 | -66.8% | 17,363 | -44.2% | 0.04% | -68.8% |
| Q3 2020 | $1,290,000 | -39.5% | 31,125 | -8.1% | 0.11% | -51.9% |
| Q1 2020 | $2,132,000 | +354.6% | 33,878 | +505.0% | 0.23% | +2230.0% |
| Q2 2018 | $469,000 | -81.7% | 5,600 | -86.6% | 0.01% | -77.8% |
| Q1 2018 | $2,565,000 | -31.2% | 41,700 | +35.4% | 0.04% | -19.6% |
| Q2 2017 | $3,728,000 | +18.0% | 30,800 | +60.4% | 0.06% | -46.2% |
| Q3 2016 | $3,160,000 | +413.0% | 19,200 | +300.0% | 0.10% | +246.7% |
| Q1 2016 | $616,000 | -60.3% | 4,800 | -12.7% | 0.03% | -79.9% |
| Q1 2015 | $1,551,000 | – | 5,500 | – | 0.15% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Samsara BioCapital, LLC | 234,375 | $23,623,000 | 22.67% |
| Boxer Capital, LLC | 600,000 | $60,474,000 | 7.47% |
| DLD Asset Management, LP | 834,600 | $84,136,000 | 5.77% |
| GREAT POINT PARTNERS LLC | 200,000 | $20,158,000 | 2.55% |
| BB BIOTECH AG | 575,719 | $58,027,000 | 1.86% |
| Elk Creek Partners, LLC | 207,657 | $20,930,000 | 1.74% |
| ALTRINSIC GLOBAL ADVISORS LLC | 277,944 | $28,014,000 | 1.34% |
| Sarissa Capital Management LP | 54,000 | $5,442,000 | 1.21% |
| QCM Cayman, Ltd. | 2,181 | $220,000 | 0.90% |
| Opus Point Partners Management, LLC | 3,534 | $356,000 | 0.78% |